Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1 alpha-p300 interaction by a small molecule
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Hyuk Sung | - |
dc.contributor.author | Kim, Da-Rae | - |
dc.contributor.author | Yang, Eun Gyeong | - |
dc.contributor.author | Park, Yong Keun | - |
dc.contributor.author | Ahn, Hee-Chul | - |
dc.contributor.author | Min, Sun-Joon | - |
dc.contributor.author | Ahn, Dae-Ro | - |
dc.date.accessioned | 2021-06-23T06:53:28Z | - |
dc.date.available | 2021-06-23T06:53:28Z | - |
dc.date.issued | 2012-08 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.issn | 1464-3405 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/32195 | - |
dc.description.abstract | Vascular endothelial growth factor (VEGF) plays a pro-angiogenic role in tumor progression. Stabilization of a key regulator termed the hypoxia inducible factor (HIF)-1 alpha under oxygen deficient environment around tumor is known to elicit expression of VEGF through binding to p300. Thus, inhibition of the HIF-1 alpha-p300 interaction would lead to down-regulation of VEGF expression, thereby providing potential cancer therapeutics. Here, we have screened a chemical library against the interaction of the HIF-1 alpha-derived peptide with p300 employing a fluorescence polarization-based assay. We have identified a compound as the most prominent inhibitor against the protein-protein interaction. Further, we have observed suppression of the mRNA level of VEGF upon treatment of HeLa cells with the compound, demonstrating its inhibitory effect at the cellular level. (c) 2012 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.title | Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1 alpha-p300 interaction by a small molecule | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.bmcl.2012.06.054 | - |
dc.identifier.scopusid | 2-s2.0-84864412437 | - |
dc.identifier.wosid | 000306962800018 | - |
dc.identifier.bibliographicCitation | Bioorganic and Medicinal Chemistry Letters, v.22, no.16, pp 5249 - 5252 | - |
dc.citation.title | Bioorganic and Medicinal Chemistry Letters | - |
dc.citation.volume | 22 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 5249 | - |
dc.citation.endPage | 5252 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | HEPATOMA-CELLS | - |
dc.subject.keywordPlus | HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | ACCUMULATION | - |
dc.subject.keywordPlus | HIF-1-ALPHA | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordAuthor | HIF-1 alpha-p300 interaction | - |
dc.subject.keywordAuthor | VEGF | - |
dc.subject.keywordAuthor | Inhibitor | - |
dc.subject.keywordAuthor | Fluorescence polarization | - |
dc.subject.keywordAuthor | Protein-protein interaction | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0960894X12008050?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.